INTRODUCTION
In the phase 3 MajesTEC-3 study (NCT05083169), teclistamab with daratumumab (Tec-Dara) significantly improved progression-free and overall survival (PFS/OS) versus investigator's choice of standard-of-care daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patient...
Larry D. Anderson, S. Nair, Mi-Jun Keng et al.· Advances in Therapy· 0 citations
Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, none have achieved the accuracy to be inc...
Rodrigo Martinez Alcala, L. Visser, C. Fortpied et al.· PLoS ONE· 0 citations
It is demonstrated that ctDNA could potentially be used for prognostication and disease monitoring in PTLD, outperforming PET/CT in 8 cases, indicating that ctDNA monitoring can complement PET/CT to guide early escalation to chemotherapy in high-risk patients, though larger cohorts are needed to validate these findings...
Y. Zhong, Nick Veltmaat, Filipe Montes de Jesus et al.· Blood Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.